EpiVario
EpiVario Inc. is developing innovative therapeutics targeting a newly identified epigenetic process involved in trauma-induced fear and stress responses and addiction-related drug cravings. This discovery provides a unique therapeutic target for addressing obstinate neuropsychiatric disorders such as PTSD and substance use disorders. Leveraging their paradigm-shifting finding, EpiVario spearheads the field with a pharmacotherapeutic designed to prevent relapse in opioid use disorder patients.
Contact Name:
Thomas Kim
Contact Email:
Website:
https://epivario.com/
City, State – Congressional District:
Philadelphia,
PA
–
3
Technology:
Drug
Funding:
Alcohol (NIAAA),
Drug Abuse (NIDA)
NIH Projects:
NIH RePorter for
EpiVario
Sponsored Event(s):
Life Sciences Summit | 2024
